Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 6/2020

01-06-2020 | Metastasis | Neuroendocrine Cancers (JR Strosberg, Section Editor)

Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions

Authors: Donna D’Souza, MBBS, MMed, Jafar Golzarian, MD, Shamar Young, MD

Published in: Current Treatment Options in Oncology | Issue 6/2020

Login to get access

Opinion statement

Liver-directed therapy should be considered for patients with unresectable liver metastases from neuroendocrine tumor if symptomatic or progressing despite medical management. Our experience and current literature shows that the bland embolization, chemoembolization, and radioembolization are very effective in controlling symptoms and disease burden in the liver, and that these embolization modalities are similar in terms of efficacy and radiologic response. Their safety profiles differ, however, with recent studies suggesting an increase in biliary toxicity with drug-eluting bead chemoembolization over conventional chemoembolization, and a risk of long-term hepatotoxicity with radioembolization. For this reason, we tailor the type of embolotherapy to each patient according to their clinical status, symptoms, degree of tumor burden, histologic grade, and life expectancy. We do not recommend a “one-size-fits-all” approach. Our general strategy is to use bland embolization as first-line embolotherapy, and radioembolization for patients with high-grade tumors or who have failed other embolotherapy.
Literature
1.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.PubMedCrossRef
2.
Dermine S, Palmieri L-J, Lavolé J, Barré A, Dohan A, Abou Ali E, et al. Non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors. J Clin Med. 2019;8(11):1907.PubMedCentralCrossRef
3.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.PubMedPubMedCentralCrossRef
4.
Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24(8):2319–25.PubMedCrossRef
5.
6.
Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2017;105(3):245–54.PubMedCrossRef
7.
Shah H, Benson AB, Lurie RH, Bergsland E, Helen Diller Family U, Berlin JD, et al. National Comprehensive Cancer Network Guidelines Version 1.2019: Neuroendocrine and Adrenal Tumors. 2019. www.​nccn.​org/​patients.
8.
Young S, Rivard M, Kimyon R, Sanghvi T. Accuracy of liver ablation zone prediction in a single 2450 MHz 100 watt generator model microwave ablation system: an in human study. Diagn Interv Imaging. 2019.
9.
Young S, Taylor AJ, Sanghvi T. Post locoregional therapy treatment imaging in hepatocellular carcinoma patients: a literature-based review. J Clin Transl Hepatol. 2018;6(2):189–97.PubMedPubMedCentralCrossRef
10.
Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the middlesex experience. Abdom Imaging. 2005;30(4):435–41.PubMedCrossRef
11.
Vogl TJ, Naguib NNN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NEA. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72(3):517–28.PubMedCrossRef
12.
Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21.CrossRefPubMed
13.
Hellman P, Ladjevardi S, Skogseid B, Åkerström G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26(8):1052–6.PubMedCrossRef
14.
Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. Am J Roentgenol. 1986;147(1):149–54.CrossRef
15.
Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–81.PubMedCrossRef
16.
Strosberg JR, Choi J, Cantor AB, Kvols LK, Lee H. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13(1):72–8.PubMedCrossRef
17.
Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, et al. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12(11):1951–60.PubMedPubMedCentralCrossRef
18.
Zener R, Yoon H, Ziv E, Covey A, Brown KT, Sofocleous CT, et al. Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes. Cardiovasc Intervent Radiol. 2019;42(4):569–76.PubMedPubMedCentralCrossRef
19.
Maire F, Lombard-Bohas C, O’Toole D, Vullierme MP, Rebours V, Couvelard A, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012;96(4):294–300.PubMedCrossRef
20.
• Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40(1):69–80 Large retrospective study comparing TAE, TACE and TARE for NELM with propensity score analysis.PubMedCrossRef
21.
Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177–82.PubMedCrossRef
22.
Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist. 2012;17(5):725–31.PubMedPubMedCentralCrossRef
23.
Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188(5):1201–7.CrossRef
24.
Dhir M, Shrestha R, Steel JL, Marsh JW, Tsung A, Tublin ME, et al. Initial treatment of unresectable neuroendocrine tumor liver metastases with transarterial chemoembolization using streptozotocin: a 20-year experience. Ann Surg Oncol. 2017;24(2):450–9.PubMedCrossRef
25.
Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O’Toole D, et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer. 2007;96(1):49–55.PubMedCrossRef
26.
Bloomston M, Al-Saif O, Klemanski D, Pinzone JJ, Martin EW, Palmer B, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11(3):264–71.PubMedCrossRef
27.
Da Dong X, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol. 2011;28(Suppl 1):S286–90.PubMedCrossRef
28.
Hur S, Chung JW, Kim HC, Oh DY, Lee SH, Bang YJ, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol. 2013;24(7):947–56.PubMedCrossRef
29.
• Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27(12):4995–5005 Large retrospective study comparing TACE and TARE for NELM with propensity score analysis.PubMedPubMedCentralCrossRef
30.
Soulen M, White S, Fidelman N, Garcia-Monaco R, Wileyto E, Avritscher R, et al. Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET): first safety report. J Vasc Interv Radiol. 2019;30(3):S49–50.CrossRef
31.
Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36(2):449–59.PubMedCrossRef
32.
Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. J Hepatol. 2012;56(3):609–17.PubMedCrossRef
33.
Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, et al. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol. 2015;38(2):372–80.PubMedCrossRef
34.
Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y -microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271–9.PubMedCrossRef
35.
Young S, Taylor A, Golzarian J, Flanagan S, D’Souza D, Sanghvi T. Clinical utility of one month imaging following selective internal radiation therapy. Diagn Interv Imaging. 2019;100(1):39–46.PubMedCrossRef
36.
• Braat A, Kappadath SC, Ahmadzadehfar H, Stothers CL, Frilling A, Deroose CM, et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413–25 Large multicenter retrospective study assessing efficacy and toxicity of radioembolization for NELM.PubMedCrossRef
37.
• Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol. 2018;100:23–9 Large systematic review study assessing efficacy and toxicity of radioembolization for NELM.PubMedCrossRef
38.
Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, et al. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016;7(6):860–74.PubMedPubMedCentralCrossRef
39.
Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251(5):910–6.PubMedCrossRef
40.
Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2018;29(6):858–65.PubMedCrossRef
41.
• Su YK, Mackey RV, Riaz A, Gates VL, Benson AB, Miller FH, et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol. 2017;28(11):1520–6. Retrospective study with long-term follow up (mean 4.1 years) demonstrating long-term hepatotoxicity is common but asymptomatic in most.PubMedCrossRef
42.
Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors - a single-institution experience. J Gastrointest Oncol. 2019;10(1):118–27.PubMedPubMedCentralCrossRef
43.
Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol. 2019;30(12):1915–23.PubMedCrossRef
44.
45.
Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol. 1999;10(Suppl 2):S3–8.PubMedCrossRef
46.
Soulen MC, Van Houten D, Teitelbaum UR, Damjanov N, Cengel KA, Metz DC. Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. Pancreas. 2018;47(8):980–4.PubMedCrossRef
47.
Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, et al. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer. 2018;124(9):1992–2000.PubMedCrossRef
48.
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590–602.PubMedCrossRef
49.
Whitney R, Valek V, Falco Fages J, Garcia A, Narayanan G, Tatum C, et al. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist. 2011;16(5):594–601.PubMedPubMedCentralCrossRef
50.
Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O’dorisio TM, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014;43(2):219–25.PubMedPubMedCentralCrossRef
51.
Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19(1):390.PubMedPubMedCentralCrossRef
Metadata
Title
Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions
Authors
Donna D’Souza, MBBS, MMed
Jafar Golzarian, MD
Shamar Young, MD
Publication date
01-06-2020
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 6/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-020-00751-x

Other articles of this Issue 6/2020

Current Treatment Options in Oncology 6/2020 Go to the issue

Lymphoma (DO Persky, Section Editor)

PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma

Neuroendocrine Cancers (JR Strosberg, Section Editor)

Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms

Leukemia (PH Wiernik, Section Editor)

Biology and Treatment of Hairy Cell Leukemia

Skin Cancer (T Ito, Section Editor)

The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma

Gynecologic Cancers (LA Cantrell, Section Editor)

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

Neuroendocrine Cancers (JR Strosberg, Section Editor)

Hereditary Syndromes in Neuroendocrine Tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits